This review considers whether probiotics are effective agents for the treatment and ⁄ or prevention of bacterial vaginosis (BV). There seems to be an association between the absence of, or low concentrations of, vaginal lactobacilli and the development of BV. Many studies have suggested that the presence of H 2 O 2 -producing vaginal lactobacilli may protect against BV, although some studies do not support this hypothesis. In-vitro studies have suggested that certain specific strains of lactobacilli are able to inhibit the adherence of Gardnerella vaginalis to the vaginal epithelium and ⁄ or produce H 2 O 2 , lactic acid and ⁄ or bacteriocins, which inhibit the growth of bacteria causing BV. Clinical trials showed that intra-vaginal administration of Lactobacillus acidophilus for 6-12 days, or oral administration of L. acidophilus or Lactobacillus rhamnosus GR-1 and Lactobacillus fermentum RC-14 for 2 months, resulted in the cure of BV (defined as a 0-1 positive score according to Amsel's criteria), and ⁄ or reduced the recurrences of BV, and ⁄ or caused an increase in vaginal lactobacilli and restoration of a normal vaginal microbiota, significantly more frequently than did a placebo, acetic acid or no treatment. However, several trials have found no significant difference in the cure rate of BV and in the number of vaginal lactobacilli after intra-vaginal instillation of lactobacilli when compared with the effect of a placebo or oestrogen. Thus, although the available results concerning the effectiveness of the administration of lactobacilli for the treatment of BV are mostly positive, it cannot yet be concluded definitively that probiotics are useful for this purpose.
I N T R O D U C T I O N
Bacterial vaginosis (BV) is a common vaginal infection causing significant gynaecological and obstetric morbidity. Apart from causing irritating symptoms, mainly a malodorous vaginal discharge, BV has been associated with pelvic inflammatory disease [1] , infections following gynaecological surgery [2] , and pre-term birth [3] . It has also been suggested that the presence of BV increases the risk for human immunodeficiency virus infection [4, 5] . Treatment with metronidazole or clindamycin, administered orally or intra-vaginally, has been followed by frequent recurrences of BV [6] . Because of its high morbidity and frequent recurrence following treatment, alternative therapeutic agents need to be sought for the treatment of BV.
Probiotics are defined as 'live microorganisms which, when administered in adequate amounts, confer a health benefit on the host' [7] . Lactobacilli are the commonest organisms used as probiotics. Since the vaginal microbiota of women with BV has been found to contain a reduced number of lactobacilli in comparison with healthy women, lactobacilli administered orally or intra-vaginally have been tested for their effectiveness in colonising the vagina and curing women with BV, or at least preventing its recurrence.
C H A N G E S I N V A G I N A L M I C R O B I O T A D U R I N G B V
The normal vaginal microbiota is normally dominated by lactobacilli, especially Lactobacillus crispatus [8] [9] [10] [11] , Lactobacillus jensenii [8, 11] , Lactobacillus iners [9, 11, 12] and Lactobacillus gasseri [8, 10, 11] . Compared with that of normal women, the vaginal microbiota of women with BV consists more commonly, and in higher numbers, of Gardnerella vaginalis, Mycoplasma hominis, Prevotella, Peptostreptococcus, Mobiluncus and Bacteroides spp., while lactobacilli are found less frequently and in lower numbers. Nugent et al. [13] suggested that BV should be diagnosed when vaginal smears examined following Gram's stain are given a score of ‡7, after adding the points (1-4+) allocated to each of the following morphotypes: lactobacilli (large Gram-positive rods), G. vaginalis (small Gram-variable rods), Bacteroides spp. (small Gram-negative rods) and Mobiluncus spp. (curved Gram-variable rods). The higher the number of the specific morphotypes per oil immersion field, the higher the number of points for each morphotype, except for lactobacilli, the absence of which obtained the highest score.
There is strong evidence that the absence of vaginal lactobacilli is associated with the development of BV. Alvarez-Olmos et al. [14] found a negative association between BV and the presence of lactobacilli in the vaginas of females aged 14-18 years (p 0.034). Similarly, vaginal lactobacilli were isolated from 73.7% of 825 women without BV, and from 29.8% of 131 women with BV (p <0.001) [15] , from 74.3% of 2729 women without BV, and from 38.4% of 445 women with BV (OR 0.7, 95% CI 0.6-0.8), in a study of pregnant women aged >18 years [16] , and from 96% of 28 women without BV, and from 52% of 67 women with BV (p <0.001) [17] .
In addition, apart from the association between an absence of vaginal lactobacilli and BV, a possible association between low concentrations of vaginal lactobacilli and development of BV has been revealed by some studies. Thus, Zariffard et al. [18] analysed the cervicovaginal lavage samples of 21 human immunodeficiency virus-positive women by real-time PCR, and found that the median number of lactobacilli was significantly lower and the median number of G. vaginalis organisms was significantly higher in five women with BV, compared with 16 women without BV [20] , H 2 O 2 -producing lactobacilli were isolated from 5% of women with BV (based on the Nugent score) and from 61% of those with a normal microbiota (p <0.001). A second study of pregnant women by Hillier et al. [21] showed that BV (based on Amsel's criteria) was significantly less common among women with H 2 O 2 -producing vaginal lactobacilli (10 ⁄ 127, 8%) than among women with non-H 2 O 2 -producing or no lactobacilli (29 ⁄ 86, 34%, and 37 ⁄ 62, 60%, respectively; p <0.001 for both comparisons). Similarly, Hawes et al. [22] found that BV developed in ten (25%) of 40 women with non-H 2 O 2 -producing vaginal lactobacilli, compared with only three (3%) of 118 women with H 2 O 2 -producing lactobacilli (p 0.02). Furthermore, a study by Antonio et al. [8] found that women with vaginal L. crispatus or L. jensenii (>94% of which were found to produce H 2 O 2 ) were significantly less likely to have BV than were women colonised by other lactobacilli (only 22% of which produced H 2 O 2 ) or women with no vaginal lactobacilli.
In contrast, some studies do not support the protective role of H 2 O 2 -producing lactobacilli against BV. In the study by Alvarez-Olmos et al. [14] among women with vaginal lactobacilli, H 2 O 2 -producing lactobacilli were isolated from 85% of 18 women with BV, and from 15% of 43 women without BV [14] . Moreover, Rosenstein et al. [23] isolated H 2 O 2 -producing lactobacilli from 11 (91.7%) of 12 pregnant women whose microbiota was indicative of BV following Gram's stain.
Some in-vitro studies have shown that specific strains of lactobacilli are able to coaggregate with G. vaginalis and block the adherence and ⁄ or displace previously adherent strains of G. vaginalis from vaginal epithelial cells. Boris et al. [24] showed that Lactobacillus acidophilus, L. gasseri and L. jensenii, isolated from the vaginal samples of healthy pre-menopausal women, coaggregated in vitro with G. vaginalis. L. acidophilus was also found to decrease the adherence and to displace previously adherent strains of G. vaginalis on vaginal epithelial cells. Mastromarino et al. [25] found that human isolates of Lactobacillus salivarius FV2 and L. gasseri 335 coaggregated in vitro with G. vaginalis, and that vaginal tablets containing a combination of these organisms with Lactobacillus brevis CD2 (which is strongly adherent to epithelial cells) reduced the adhesion by 57.7% and displaced 60.8% of G. vaginalis cells attached previously.
Some Lactobacillus strains have also been found to have an inhibitory effect on the in-vitro growth of pathogens that cause BV, which may be caused, in part, by the production of H 2 O 2 . Mastromarino et al. [25] found that L. salivarius FV2 and L. gasseri 335, isolated from the human vagina, produced large amounts of H 2 O 2 and inhibited the growth of G. vaginalis. McLean and Rosenstein [26] showed that L. acidophilus 48101, isolated from the vagina of healthy women, produced large amounts of H 2 O 2 and inhibited (although by less than the mean + SD) the growth of Bacteroides spp., Prevotella bivia and G. vaginalis isolated from vaginal swabs of women with BV.
Production of lactic acid by lactobacilli, which is mainly responsible for the low vaginal pH, contributes, probably even more than production of H 2 O 2 , to the inhibition of growth of G. vaginalis. An in-vitro study by McLean and McGroarty [27] showed that the bacteriostatic effect of L. acidophilus on G. vaginalis NCTC 11292 was reduced by 60% after increasing the culture pH by the addition of NaOH, and by 30% after denaturing H 2 O 2 with catalase. Thus, production of lactic acid, which was mainly responsible for the low pH, and, to a lesser degree, production of H 2 O 2 by L. acidophilus, affected the growth inhibition of G. vaginalis significantly. Klebanoff et al. [28] found that H 2 O 2 -producing lactobacilli at high concentrations inhibited the growth of G. vaginalis and Bacteroides bivius. Catalase inhibited the toxicity of H 2 O 2 -producing lactobacilli, but not that of non-H 2 O 2 -producing lactobacilli. Lower concentrations of H 2 O 2 -producing lactobacilli were toxic for G. vaginalis, but only when combined with myeloperoxidase and chloride, which have both been found in cervical mucus. The highest toxicity of this combination was obtained at pH 5-6. A pH of £4.5 had, by itself, an inhibitory effect on the growth of G. vaginalis, which was increased when the above combination was added.
Finally, production of bacteriocins by some Lactobacillus strains has also been found to play a role in the inhibition of growth of G. vaginalis, at least in vitro. Aroutcheva et al. [29] tested 22 Lactobacillus strains and found that 80% produced a bacteriocin that inhibited the growth of G. vaginalis. Simoes et al. [30] showed that the growth of 28 (78%) of 36 clinical isolates of G. vaginalis was inhibited by a bacteriocin-producing L. acidophilus strain, and characterised these G. vaginalis isolates as bacteriocin-susceptible.
C L I N I C A L T R I A L S
Several clinical trials have been performed to investigate whether specific strains of lactobacilli, administered either orally or intra-vaginally, are able to colonise the vaginas of women with symptomatic or asymptomatic BV, to reduce the colonisation of pathogens, and to improve symptoms and ⁄ or signs of BV when they are present. Table 1 summarises the main characteristics and outcomes of randomised controlled trials (RCTs) that have been conducted with the aforementioned purpose.
Some RCTs have suggested that intra-vaginal administration of L. acidophilus for 6-7 days cures women with BV significantly more frequently than administration of a placebo, administration of acetic acid, or no treatment. Cure of BV was defined by the absence or presence of only one of Amsel's criteria, which are vaginal fluid with a pH >4.5, a thin homogeneous greyish-white adherent discharge, a fishy odour on addition of potassium hydroxide 10% w ⁄ v to the discharge (a positive amine test or sniff ⁄ whiff test), and clue cells on a saline wet mount [31] . Hallen et al. [32] found that significantly more women with BV were cured 7-10 days after the start of treatment with L. acidophilus when compared with those treated with a placebo. Restoration of a normal vaginal microbiota was established in significantly more (57%, 16 ⁄ 28) women with BV who were treated with L. acidophilus than in those receiving a placebo (none of 29). Another RCT involving pregnant d Lactobacilli or placebo were administered 2-3 days after the end of anti-infective therapy (oral metronidazole for trichomoniasis and BV; oral fluconazole ± local ketoconazole for candidiasis). e Normal flora index (NFI) was calculated by allocating a value from 0 to 3 to each of the following parameters: number of lactobacilli, number of leukocytes, number of pathogenic microorganisms and pH of vaginal secretion, and then adding the values together. The higher the NFI, the healthier the vaginal flora. The degree of purity of the vaginal flora (lactobacillary grade) was estimated as follows: grade I, dominant lactobacilli, no other bacteria; grade II, lactobacilli and other bacteria; grade III, few or no lactobacilli and other bacteria; and grade IV, no lactobacilli, no other bacteria. f Lactobacilli or placebo were administered during the menstruation period following administration of clindamycin 100 mg ⁄ day vaginally for 3 days. VVC, vulvovaginal candidiasis.
Finally, L. acidophilus was administered intramuscularly in a small prospective cohort study by Pattman et al. [45] . Three 0.5-mL injections at 2-weekly intervals were administered to eight women with recurrent BV (more than two episodes during the 6-month period preceding the study) who had been treated with oral metronidazole. Six women were treated concurrently with metronidazole. Four (50%) of these women had no episodes of BV for 6 months, two had a recurrence of BV within 3 months of completing treatment, but had no more episodes after being treated with metronidazole, and one had two recurrences, received one additional injection with L. acidophilus, and remained asymptomatic for the following 6 months. Clue cells were replaced by lactobacilli in all women who reported improvement of their symptoms.
C O N C L U S I O N S
Various in-vitro studies have shown that specific strains of lactobacilli inhibit the growth of bacteria causing BV by producing H 2 O 2 , lactic acid, and ⁄ or bacteriocins, and ⁄ or inhibit the adherence of G. vaginalis to the vaginal epithelium. Most relevant clinical trials have suggested that oral administration of L. acidophilus, or intra-vaginal administration of L. acidophilus or L. rhamnosus GR-1 and L. fermentum RC-14, is able to increase the numbers of vaginal lactobacilli, restore the vaginal microbiota to normal, and cure women of BV, although several trials found that intravaginal instillation of lactobacilli had no significant effect on the treatment of BV. In most of the relevant RCTs, lactobacilli were compared with a placebo, in two RCTs with acetic acid, and in one RCT with no treatment. Interestingly, in only one RCT [39] were lactobacilli compared with metronidazole. However, further RCTs, including larger samples of women with BV, in which lactobacilli are compared either with a placebo or metronidazole, need to be conducted before it will be possible to reach definitive conclusions as to whether probiotics represent an effective and safe method for treating women with BV.
